Cyanotech (Cyanotech) Change In Working Capital : $1.98 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Cyanotech Change In Working Capital?

Cyanotech's change in working capital for the quarter that ended in Dec. 2023 was $-0.52 Mil.

Cyanotech's change in working capital for the fiscal year that ended in Mar. 2023 was $-1.17 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Cyanotech Change In Working Capital Historical Data

The historical data trend for Cyanotech's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyanotech Change In Working Capital Chart

Cyanotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Working Capital

Get a 7-Day Free Trial

0.45

-2.03

0.39

-2.15

-1.17

Cyanotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.23	1.40	0.18	0.93	-0.52

Cyanotech Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.98 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Cyanotech Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Cyanotech's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyanotech (Cyanotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Cyanotech Corp (OTCPK:CYAN) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

73-4460 Queen Kaahumanu Highway, Suite 102, Kailua-Kona, HI, USA, 96740

Website

https://www.cyanotech.com

Cyanotech Corp is engaged in the production of natural products derived from microalgae for the nutritional supplements market. The company's products include BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica is a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. BioAstin Hawaiian Astaxanthin is a dietary antioxidant shown to support and maintain the body's natural inflammatory response, enhance skin, and support eye and joint health. It derives maximum revenue from the Packaged product and geographically from the United States.

Executives

Kakuk Collette Nicole	officer: Chief Strategic Comml Officer	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Michael A / Davis	director, 10 percent owner	1621 JUANITA LANE, TIBURON CA 94920
Angela May Mcelwee	director	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Charles Jason Hartmann	officer: VP, Sales & Marketing	73-4460 QUEEN KAAHUMANU HWY SUITE 102, KAILUA-KONA HI 96740
Glenn Jensen	officer: VP-Operations	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA-KONA HI 96740
Jennifer M. Johansen	officer: VP of Quality	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Walter Bennett Menzel	director	45 MOUNT TIBURON ROAD, TIBURON CA 94920
Felicia I Ladin	officer: CFO, VP Fin & Admin, Treasurer	26 CORPORATE CIRCLE, ALBANY NY 12203
Matthew Keith Custer	officer: Vice President, Gen Mgr	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA HI 96740
Amy Beth Nordin	officer: VP, HR, Secretary	73-4460 QUEEN KAAHUMANU HWY. SUITE 102, KAILUA-KONA HI 96740
Brian Brett Orlopp	officer: CFO, VP, Treasurer, Secretary	73-4460 QUEEN KAAHUMANU HWY #102, KAILUA KONA CA 96740
Gerald J Watts	officer: COO	2530 RED HILL AVE, SANTA ANA CA 92705
Mawae Morton	officer: President	7473 MAKA'A STREET, HONOLULU HI 96825
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
David M Mulder	director	21771 CALATRAVA, MISSION VIEJO CA 92692